Evelo Biosciences, Inc. (EVLO) is a Biotechnology company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 28/100, indicating a weak investment profile with 0 out of 7 criteria passed.
Net income is $115M (loss), growing at -11.2%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $51M with negative equity of -$5M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 4.16 (strong liquidity). Debt-to-assets is 79.4%. Total assets: $64M.
Analyst outlook: 5 / 8 analysts rate EVLO as buy (63%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 28/100 (Fail), Future 55/100 (Partial), Income ?/100 (Fail).
